The CMA has opened an invitation to comment until 3 June for parties involved.
The FTSE 100 pharma giant has received approval in the US, Canada, Brazil, Russia but was still waiting for the green light from the UK, the EU and Japan.
The megadeal was announced in December so the Anglo-Swedish group could boost its growing presence in immunology.
The deal will see Alexion shareholders paid US$175 for each share, made up of US$60 in cash and 2.1243 American depositary shares (ADSs), which each represent one-half of one ordinary AstraZeneca share.
Shares in the firm were flat at 8,111p on Tuesday morning.
This is the first time a nasally administered antibody has been given to a patient with SPMS
Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said it has begun treating a patient with secondary progressive multiple sclerosis using nasally-administered Foralumab, the company’s fully-human anti-CD3 monoclonal antibody.
The drug will be provided under the Food & Drug Administration’s individual patient expanded access protocol overseen by researchers at the Brigham and Women s Hospital (BWH), Harvard.
This is the first time a nasally administered antibody has been given to a patient with SPMS.
Sufferers of multiple sclerosis have limited treatment options with Tysabri, sold by Biogen Inc (NASDAQ:BIIB), one of the few drugs offering relief.
Apollon Formularies PLC (LON:APOL) Chairman and CEO Dr Stephen Barnhill, who also serves at Chairman at Aion Therapeutic Inc (CSE:AION) tells Proactive.
Snapshot
Arecor awarded £2.8m from Innovate UK to accelerate fight against diabetes
About the company
Arecor is ‘advancing today’s therapies to enable healthier lives’ by developing a broad portfolio of therapies for its proprietary pipeline and in partnership with leading pharmaceutical and biotech companies
How it is doing 17 May 2021
Arecor is planning to debut on AIM with a £20mln IPO next month to boost its pipeline of diabetes treatment.
The biopharmaceutical group was recently awarded a £2.8mln grant from Innovate UK to support the Phase II development of AT247.
The candidate is an ultra-rapid acting insulin product based on the biopharma company’s proprietary Arestat technology platform.